Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
FREQ

FREQ - Frequency Therapeutics Inc Stock Price, Fair Value and News

$0.31+0.01 (+3.33%)
Market Closed

82/100

FREQ

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

82/100

FREQ

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$0.48

Target 3M

$0.4

Target 6M

$0.43

FREQ Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

FREQ Price Action

Last 7 days

28.0%

Last 30 days

45.5%

Last 90 days

6.7%

Trailing 12 Months

45.5%

FREQ RSI Chart

FREQ Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

FREQ Valuation

Market Cap

2.9M

Price/Earnings (Trailing)

-0.03

Price/Sales (Trailing)

1.24

EV/EBITDA

0.25

Price/Free Cashflow

-0.04

FREQ Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$0.48

Target 3M

$0.4

Target 6M

$0.43

FREQ Fundamentals

FREQ Revenue

Revenue (TTM)

2.3M

FREQ Earnings

Earnings (TTM)

-88.4M

Earnings Growth (Yr)

13.99%

Earnings Growth (Qtr)

29.91%

FREQ Profitability

EBT Margin

-3888.73%

Return on Equity

-89.28%

Return on Assets

-54.73%

Free Cashflow Yield

-2.4K%

FREQ Investor Care

Shares Dilution (1Y)

0.52%

Diluted EPS (TTM)

-9.4

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20250000
2024008.2M2.3M
202134.4M35.3M24.0M14.1M
202036.8M44.7M31.7M37.0M
201900028.9M
Get all data in R, Python etc through our Historical Stock Data APIs

About Frequency Therapeutics Inc

FREQ
Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules to activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIb clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. The company has a license and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, the Massachusetts Institute of Technology, and The Scripps Research Institute. Frequency Therapeutics, Inc. was incorporated in 2014 and is headquartered in Lexington, Massachusetts.
 CEO
 WEBSITEfrequencytx.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES46

Frequency Therapeutics Inc Frequently Asked Questions

FREQ is the stock ticker symbol of Frequency Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Tue Jan 27 2026, market cap of Frequency Therapeutics Inc is 2.92 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check FREQ's fair value in chart for subscribers.

The fair value guage provides a quick view whether FREQ is over valued or under valued. Whether Frequency Therapeutics Inc is cheap or expensive depends on the assumptions which impact Frequency Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for FREQ.

As of Tue Jan 27 2026, FREQ's PE ratio (Price to Earnings) is -0.03 and Price to Sales (PS) ratio is 1.24. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. FREQ PE ratio will change depending on the future growth rate expectations of investors.